Skeletal metastases develop in up to 70% of women who will die from breast cancer (1), causing considerable suffering and morbidity because of life-threatening hypercalcemia, pathological fractures, cord compression, and intractable pain (2, 3) . Paget proposed the "seed and soil" hypothesis (4) over a hundred years ago, speculating that tumor cells (seed) provide growth factors activating bone microenvironment (soil), producing growth factors that feed tumor cells in a cycle of mutual cooperation (2, 3) .
Osteoblast receptor activator of nuclear factor-kB ligand (RANKL) is a critical mediator of bone turnover expressed by the osteoblast subsequently activating osteoclast and bone resorption (5, 6) . Osteocytes also produce RANKL, challenging the paradigm that only osteoblasts are capable of RANKL production (7) . The "seed and soil" hypothesis is supported by the recent discovery that tumor cells activate RANKL production (8) (9) (10) . RANKL activates osteoclast precursors into maturation and activation. Once osteoclasts are activated, osteolysis takes place, causing release of calcium, bone-derived transforming growth factor-β (TGF-β), and insulin-like growth factor 1 (IGF-1). These factors bind to cell surface receptors on tumor cells and promote their proliferation. This vicious cycle facilitates the establishment of metastases to the skeleton (11) (12) (13) .
Bisphosphonates, potent inhibitors of bone turnover, are used to manage skeletal metastases (14) . Bisphosphonates, analogs of inorganic pyrophosphate, prevent bone resorption by causing osteoclast apoptosis through inhibition of the mevalonate pathway to isoprenoid lipids synthesis (15) . They are approved for the management of postmenopausal osteoporosis, which occurs in approximately 60% of women 65 years and older, however, a much smaller proportion of women with osteoporosis in this age group will be treated, and over 50% of women started on bisphosphonates will discontinue therapy within a year (16) . In women with breast cancer and established bone metastases, treatment with bisphosphonates can delay further skeletal-related events (17, 18) . Pamidronate and zoledronate are two potent aminobisphosphonates approved by the US Food and Drug Administration for the management of skeletal metastases. These two agents do not eradicate lesions; they reduce by 20% the proportion of patients experiencing further skeletal-related events (18) . Table 1 summarizes the randomized trials that have evaluated bisphosphonates approved for the treatment of bone metastases (clodronate, pamidronate, and zoledronate) in a secondary prevention framework. Ten trials were identified with heterogeneity across studies in several important features: entry into study varied from 1990 to 2008 (19) (20) (21) (22) (23) (24) ; proportion of postmenopausal women ranged from 0% to 61% (20) (21) (22) (23) 25) with two studies (26, 27) inducing menopause with Letrozole (2.5 mg); and duration of follow-up ranged from four to 10 years (21, 22, 25) . Also, the dose was higher than that used for osteoporosis, and treatment duration ranged from two to five years (20, 23) . The outcomes were bone metastases, deaths from all causes, and disease-free survival. Two of the 10 studies (28, 29) showed a statistically lower occurrence of bone metastases in the treated group, but in the Paterson study (29) the effect was statistically significant only for women 50 years of age and older.
In a recently presented meta-analysis of 41 randomized trials (placebo or open control) involving individual data on 17 751 women (10 540 who were postmenopausal), Coleman et al. (30) reported a protective effect of bisphosphonate on bone metastases of 0.79 (standard error [SE] = 0.07, P = .002) for all women and an even stronger effect for postmenopausal women, 0.65 (SE = 0.08, P = .00001). The overall bone metastasis event rate was 4.8% (n = 825); for postmenopausal women, the event rate was 4.2% (n = 445).
Other bisphosphonates, such as alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva) (31) , are approved for the treatment of established postmenopausal osteoporosis but have not been tested in a prevention framework in the context of cancer and bone metastasis. If there is an association between bisphosphonate use for osteoporosis and reduction in incidence of bone metastases, we hypothesize that this would support the "soil and seed" mechanism proposed by Paget.
The purpose of this study is to estimate the extent to which the use of oral bisphosphonates, presumably for treatment or prevention of osteoporosis, reduces the development of bone metastases among women with breast cancer.
Methods

Design and Population
This is a prospective study of a historical cohort comprising all (n = 21 664) women in the Province of Quebec who had been diagnosed with breast cancer from 1998 to 2005 with follow-up to 2007. The cohort was identified using Quebec's hospitalization database (MedEcho), which forms the basis for the Quebec Tumour Registry. Prediagnosis information and follow-up of the cohort was achieved by linkage, using a unique identifier, to the province's billing database, maintained by the Regie d'assurance medicale de Québec (RAMQ) for physician services and prescriptions filled.
The cohort was originally formed for a study of waiting times for breast cancer surgery (32) 
Measures
The principle outcome was a diagnostic code for bone metastases (ICD-9: 198.5) or an indication that a prescription was filled for intravenous zoledronate or pamidronate, or oral clodronate. Women were censored when reaching this endpoint, at death, or on December 31, 2007 when follow-up ended. A secondary outcome was all-cause mortality, divided into cancer and noncancer deaths.
The exposure was based on a prescription filled for a bisphosphonate as recorded in the RAMQ database. Drug insurance is mandatory for people in Quebec and for those not covered by private insurance through their employer, the provincial government covers the cost of drugs with a copayment system not exceeding $563 per year. People over 65 years of age and those on income assistance are covered by the government drug insurance, as are people (of any age) working for companies that do not offer private insurance; 60% of all women with breast cancer had drug insurance. We identified the length of time people were covered by the government drug insurance plan when quantifying exposure to bisphosphonate. Drugs dispensed were considered to be drugs consumed.
The drugs studied were alendronate, risedronate, and etidronate. Two time periods were defined for bisphosphonate use: prediagnosis and postdiagnosis. Prediagnosis was the period two years prior and was defined as a binary variable for the exposed or not. As there is a potential paradox with follow-up studies with censoring arising as a result of persons not developing the outcome of interest having the longest timeframe during which drug exposure could occur, drug exposure was a cumulative index considering time in view before event or censoring. For every month in view, a woman was assigned a value of 0 or 1 depending on whether or not she filled a prescription for a bisphosphonate during the follow-up period, and this value is added to each month's cumulative value. Also identified was whether the bisphosphonate use was associated with a bone-mineral density test indicating prevention or treatment of osteoporosis.
Confounding variables were age, comorbidity, number of ambulatory medical visits in the two years prior to diagnosis of breast cancer, financial resources, and concurrent-use medications for bone health and cancer. Comorbidity was defined using Table 1 . Salient features of previous randomized trials on bisphosphonates and prevention of bone metastases in women with breast cancer the Charlson Index (33) for administrative data and was defined at the time of the index hospitalization (cancer not included). Medical visits were considered a proxy for health-seeking behavior, potentially increasing opportunity for prescription of a bisphosphonate. Concurrent medications were defined as binary variables for any use in the two years prior to diagnosis and up to 60 days before occurrence of a bone metastasis.
Statistical Analysis
Cox proportional hazards was used to model the time to develop bone metastases as a function of exposure to bisphosphonate as a four level variable: no use, prediagnosis only, postdiagnosis only, and both pre-and postdiagnosis with adjustment for confounders. The proportionality assumption of constant hazard over time was verified, and there was some violation in the strata defined by regional disease for the two exposure groups covering postdiagnosis drug use. However, these two groups had very small numbers, producing instability of the estimates. Stage was dealt with by stratification (by local or regional disease at time of diagnosis). Adjusted survival probabilities were plotted with covariates set at these levels: age, 50 to 64 years; financial resources, lowest level, 5; comorbidity, Charlson value, 1; outpatient medical visits, 0 to 9; and all other drug use, none. Absolute risk reductions were calculated from the population-based rates, and number needed to treat (NNT) was calculated as 1/risk difference. Risk was also modeled as a function of cumulative dose of bisphosphonates and reported as a linear test-for-trend.
We have chosen to report confidence intervals rather than P values. The 95% confidence intervals (CIs) that we provide could be considered equivalent to two-sided hypothesis tests.
results
The Breast Cancer Cohort comprised 21 664 women with a median follow-up time of five years (maximum 10). Table 2 shows that more than three quarters of the cohort had local disease at diagnosis; approximately 40% of the cohort was under the age of 65 years; 9.0% in the cohort were defined by local disease, and 13.8% in the cohort with regional disease were under 50 years of age. The age distribution between the two cohorts defined by stage was quite similar, as was the distribution of financial resources. Also presented is information of use of drugs known to affect either breast cancer or bone health or both. Table 3 shows that approximately 25% of the population used bisphosphonates, where the majority of use was postdiagnosis only. Among women with local disease, the incidence of bone metastases was 4.5% (745 women), and the median time to occurrence was 33 months; in women with regional disease, the incidence was 14.2%, with a median time to occurrence of 30 months (692 women). Across the different categories of drug use, both incidence and time-to-occurrence varied. For example, among women with local disease and considering women without any bisphosphonate use as the comparison (with an incidence of 5% and a median time to occurrence of 33 months), taking bisphosphonate prediagnosis and then stopping (pre-Dx only) was associated with a higher occurrence rate (8.5%) and a shorter median time to occurrence (15 months). In contrast, taking bisphosphonate postdiagnosis was associated with a reduction in incidence of bone metastases (2.8%) and a longer median time to occurrence (45 months). Also shown is the all-cause mortality proportion and cause-specific mortality.
The hazard ratios (HRs) associated with time-to-occurrence for three outcomes (bone metastases, overall survival, and cancer-related survival) are presented in Table 4 , with adjustment for key covariates. In women with local disease, taking bisphosphonate during the prediagnosis period and then stopping (pre-Dx only) is associated with a doubling of the risk of developing bone metastases (HR = 2.03, 95% CI = 1.26 to 3.26). However, taking bisphosphonates postdiagnosis only (HR = 0.55, 95% CI = 0.44 to 0.69) or continuing postdiagnosis bisphosphonates started prior to the diagnosis of breast cancer (HR pre-and post-Dx = 0.72, 95% CI = 0.53 to 0.98) were both associated with a reduction in risk of bone metastases, translating to 45% and 28% reductions, respectively. In women with regional disease, postdiagnosis exposure, with or without prediagnosis exposure, was protective, with almost a 50% reduction in risk (1-HR). Table 4 also shows that bisphosphonates have an effect on allcause mortality similar to that of development of bone metastases. An increased risk associated with exposure to bisphosphonates only prediagnosis is observed (HR = 1.37; 95% CI = 1.07 to 1.76), as is a decreased risk postdiagnosis (HR = 0.48, 95% CI = 0.42 to 0.54). Similar effects were seen for women with regional disease. The same pattern was repeated for cancer-related deaths.
The estimates in Table 4 are adjusted for key covariates. Data on the impact of demographic variables on each of the outcomes (bone metastases, all cause mortality, and cancer-related mortality) are presented in Table 5 . With age category 50 to 64 years as the referent group, women with local disease between 40 and 49 years had a higher risk of bone metastases (HR = 1.42, 95% CI = 1.10 to 1.84). For other outcomes, and also for women with regional disease, there was an increasing risk of mortality with increasing age. Comorbidity was associated with higher risk of mortality, but had no effect on bone metastases. We adjusted for health visits as a proxy for health-seeking behavior, but this variable had no effect on any outcomes (data not shown). Financial resources (highest two quintiles vs lowest quintile) were associated with a decreased risk for all outcomes but only for women with local disease. Figure 1 shows the adjusted survival curves for each of the outcomes (time-to-bone metastases, overall survival, and cancerrelated survival) separately for women with local or regional disease.
Supplementary Figure 1 (available online) shows the results of the dose analysis. For women with local disease, there was a statistically significant dose-response trend relating increasing use to lower risk (slope = 0.94, 95% CI = 0.90 to 0.99). This translates to a 4% reduction in risk for every decile of bisphosphonate use; so with 100% use, the estimated risk reduction would be 40%. In women with regional disease, there was no consistent dose-response trend.
The data presented in Table 3 was used to calculate absolute risk reductions associated with use of bisphosphonates. For women with local disease, the absolute risk of bone metastases with no drug use was 5.0% and 2.8% for use postdiagnosis, for an absolute risk Referent Referent * Index of financial resources as estimated from residential area. Quintiles 3 and 4 were not statistically significantly different from Quintile 5. All estimates of the hazard ratio are adjusted for health visits within two years prior to diagnosis of breast cancer; no statistically significant association with outpatient visits (data not presented). CI = confidence interval; HR = hazard ratio. Figure 1 . Survival probability curves for bone metastases, all-cause mortality, and cancer mortality according to four levels of bisphosphonate use (none, prediagnosis only, postdiagnosis only, and both pre-and postdiagosis) (A-F). Estimates of hazard ratios and 95% confidence intervals are derived from Cox proportional hazards model separately for women with local and regional disease, with covariates set at: age 50 to 64 years; financial resources lowest level, 5; comorbidity Charlson value, 1; outpatient medical visits, 0 to 9; and all other drug use, none. BC = breast cancer.
reduction of 2.2%. This translates to an NNT of 45. For women with regional disease, the absolute risks of bone metastases are higher, 15.8% for no use and 9.6% for postdiagnosis use, for a risk reduction of 6.2% (NNT = 16).
Discussion
Bone is a favorable microenvironment for tumor cells because of its natural abundance of growth factors/cytokines. When seeded in bone, tumor cells release their own growth factors/cytokines, which in turn accelerates bone turnover (2, 4) feeding the tumor cells with additional growth factors, creating a vicious cycle. Reducing bone turnover would theoretically reduce the amount of growth factor available to feed tumor cells. We found that use of bisphosphonates for osteoporosis prevention or treatment was associated with a reduced risk of developing bone metastases in women diagnosed with breast cancer and improved overall and cancer-related survival. Our study is comprised predominantly of postmenopausal women in whom bone turnover is generally high and provides a favorable milieu for bone metastasis development. We also had a mix of women with earlyand late-stage cancers with a ratio of 3:1.
The main difference between our study and the previous trials is that our bisphosphonate treated group, 25% to 30% of the study population, would likely have had had low bone mass (osteopenia or osteoporosis) and high bone turnover. In fact, 92% (prediagnosis) and 95% (postdiagnosis) of women had had a bone mineral density test overlapping in time with bisphosphonate prescription. This suggests that the risk reduction is strongest in the group with the most vulnerable bones. Two trials (19, 23) excluded women with history of skeletal disease or exposure to bisphosphonates, so they would have had no women with low bone mass. An urgent area of further clinical and research development would be to evaluate the effect of bisphosphonate considering bone status.
A recent clinical trial in prostate cancer (34) using a monoclonal antibody against RANKL (Denosumab 120 mg every four weeks) showed a protective effect against the development of bone metastases (HR = 0.85, 95% CI = 0.73 to 0.98). These results are in agreement with ours.
In an observational study, interpretation is complicated by the influence of confounding variables, measured and unmeasured, and, consequently, the mechanism is more difficult to tease out. The estimates derived from an observational study could reflect unmeasured confounding by indication; that is, prescription of a bisphosphonate may be a marker of better health care, which is protective. We adjusted for several variables that themselves are indicators of superior health care: health visits in the two years prior to diagnosis, comorbidity, cancer or bone-related drugs, and wealth. These variables actually had little confounding effect for the association of bisphosphonates on bone metastases or on mortality. The potential confounding effect of aromatase inhibitors was not an issue and was not included, as they were not approved in Canada for breast cancer during the study period.
This was an observational study based on administrative data; no clinical data was available. However, stage can be determined from health service use coding as can ER status from use of antiestrogen therapy. Treatments received by this population have been previously presented (35, 36) . All had had surgery to remove the tumor and would have had the appropriate adjuvant treatment (radiotherapy and chemotherapy) for cancer stage; 85% had radiotherapy, and 25% had chemotherapy, consistent with practice guidelines. As subsequent treatment was the standard of care, it would not have varied according to bisphosphonate status at time of diagnosis and, hence, would not be considered a confounder.
The effect of bisphosphonates on bone metastases is consistent with the "seed and soil" hypothesis, but the wider effect on all cause-and cancer-related mortality needs further explanation. The effect of antiresorptive agents, including bisphosphonates, strontium ranelate, and denosumab, in postmenopausal women with osteoporosis on mortality has been the subject of a 2010 meta-analysis. A 10% reduction in mortality was observed across all drug classes. Several mechanisms underlying this beneficial effect have been proposed (37) . An interesting potential mechanism is the inhibitory effect of bisphosphonates on the mevalonate pathway, the same pathway through which statins exert their beneficial effect on vascular function in vitro (38) . The beneficial effect on cardiovascular mortality supports this mechanism. Bisphosphonates are known to be preferentially taken up by bone with minimal uptake in extraskeletal tissues, thus reducing the potential for side effects.
A relevant question is the relationship between time on bisphosphonate and bone metastases. This was examined only for the postdiagnostic period, because there was a fixed look-back period of two years. Although prescribed postdiagnosis for osteoporosis and not for prevention of bone metastases, our data supports that more time on bisphosphonate results in greater reduction of bone metastases in women with local disease (Supplementary Figure 1 , available online). While the trend was similar for women with regional disease, the sample size was much smaller and the dose trend was not statistically significant.
Our study is not without limitations, particularly those associated with observational data, as indicated above. Also, it is not possible to obtain accurate information on staging or any other clinical data, apart from diagnoses, drugs dispensed, reimbursable health care visits, and fact of tests and procedures, but not results. Also, drugs dispensed are not drugs consumed.
In conclusion, our findings indicate an association between lowdose oral bisphosphonates administered for prevention or treatment of postmenopausal osteoporosis and a lower risk of skeletal metastasis in women with either early-or more advanced-stage breast cancer. The association was also dose dependent among women with local disease. An association between bisphosphonate use and improved survival was also observed and merits further investigation. 
